Ovagen vs Larazotide Acetate
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
OvagenRecovery & Repair
Larazotide Acetate- Summary
- Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Local gut action; minimal systemic exposure
- Admin Route
- SubQ, Oral
- Oral
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 0.5-2 mg
- Frequency
- Daily for 10–30 days
- 3x daily
- Key Benefits
- Hepatoprotective effects against toxic, viral, and metabolic liver damage
- Promotes hepatocyte regeneration and liver tissue repair
- May reduce liver fibrosis progression
- Supports liver metabolic function and detoxification capacity
- Anti-aging effects on hepatic tissue
- Useful in NAFLD/MASH supportive protocols
- Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No clinically significant hepatotoxicity reported
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Stacks With
- —
- —